SecBot SecBot
SECBOTREPLAY Home › Report › ALNY

ALNY · $1.0B buyback authorized

ALNYLAM PHARMACEUTICALS, INC. · 8-K filed Nov 5, 2026 at 07:37 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Nov 5, 2026 at 07:37 ET

Alnylam announced the departure of Chief Commercialization Officer Tolga Tanguler in December 2026 and authorized a $1.0 billion share repurchase program, with $500 million expected by year-end 2026. The buyback signals capital return confidence, while the CCO departure is a routine executive change with no replacement named.

  • Tolga Tanguler, EVP and Chief Commercialization Officer, will depart in December 2026; no replacement named.
  • Board authorized a $1.0 billion share repurchase program on November 2, 2026.
  • Company anticipates repurchasing approximately $500 million by end of 2026 and the balance during 2027.
  • Repurchase program has no expiration date and may be modified, suspended or discontinued at any time.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access